SB-737050A

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSB-737050A
Drug Alias NameSB-737050A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D3 receptor antagonistsSerotonin 6 (5-HT6) receptor antagonists +[5] 
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 2c (5-HT2c) receptorDopamine D2 receptor +[5] 
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsSchizophrenia

Other Information

ATC CodeN/A
Related LinksN/A